 Neurocrine Biosciences beat third-quarter forecasts and raised its Ingrezza outlook for 2022, leading NBIX stock to jump Tuesday. The post Blazing Hot Neurocrine Biosciences, With 35 Run This Year, Extends Breakout On Quarterly Beat appeared first on Investors Business Daily. 